These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 19442129

  • 1. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Stephan C, Dauer B, Khaykin P, Stuermer M, Gute P, Klauke S, Staszewski S.
    Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
    [Abstract] [Full Text] [Related]

  • 2. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
    Ferrer E, Gatell JM, Sanchez P, Domingo P, Puig T, Niubo J, Cortes C, Veloso S, Pedrol E, Leon A, Gutierrez M, Podzamczer D.
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):931-4. PubMed ID: 18671476
    [Abstract] [Full Text] [Related]

  • 3. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C.
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [Abstract] [Full Text] [Related]

  • 4. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM, Bonjoch A, Iribarren J, Galindo MJ, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B, HIV Conference Call Study Group.
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [Abstract] [Full Text] [Related]

  • 5. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W, CNAAB3005 International Study Team.
    JAMA; 2001 Mar 07; 285(9):1155-63. PubMed ID: 11231744
    [Abstract] [Full Text] [Related]

  • 6. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
    d'Ettorre G, Zaffiri L, Ceccarelli G, Andreotti M, Massetti AP, Vella S, Mastroianni CM, Vullo V.
    HIV Clin Trials; 2007 Mar 07; 8(3):182-8. PubMed ID: 17621465
    [Abstract] [Full Text] [Related]

  • 7. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M, Staszewski S, Doerr HW.
    Antivir Ther; 2007 Mar 07; 12(5):695-703. PubMed ID: 17713153
    [Abstract] [Full Text] [Related]

  • 8. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R, Calza L.
    AIDS Patient Care STDS; 2008 Apr 07; 22(4):279-90. PubMed ID: 18290748
    [Abstract] [Full Text] [Related]

  • 9. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, AIDS Clinical Trials Group Study A5202 Team.
    N Engl J Med; 2009 Dec 03; 361(23):2230-40. PubMed ID: 19952143
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
    Rey D, Krebs M, Partisani M, Hess G, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Lang JM.
    J Acquir Immune Defic Syndr; 2006 Dec 15; 43(5):530-4. PubMed ID: 17057610
    [Abstract] [Full Text] [Related]

  • 13. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
    Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, Horton J, Ha B, Lanier ER, Elion R, COL40263 study.
    J Antimicrob Chemother; 2010 Feb 15; 65(2):307-15. PubMed ID: 20008905
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.
    Cochrane Database Syst Rev; 2013 Jun 05; 2013(6):CD008270. PubMed ID: 23740608
    [Abstract] [Full Text] [Related]

  • 16. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS, ESS30009 Study.
    J Infect Dis; 2005 Dec 01; 192(11):1921-30. PubMed ID: 16267763
    [Abstract] [Full Text] [Related]

  • 17. Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
    d'Ettorre G, Mastroianni CM, Massetti AP, Lichtner M, D'Agostino C, Vullo V.
    AIDS; 2005 May 20; 19(8):841-2. PubMed ID: 15867503
    [No Abstract] [Full Text] [Related]

  • 18. Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
    Mastroianni CM, d'Ettorre G, Vullo V.
    Expert Opin Pharmacother; 2006 Nov 20; 7(16):2233-41. PubMed ID: 17059380
    [Abstract] [Full Text] [Related]

  • 19. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
    Sprenger HG, Langebeek N, Mulder PG, Ten Napel CH, Vriesendorp R, Hoepelman AI, Legrand JC, Koopmans PP, Van Kasteren ME, Bravenboer B, Ten Kate RW, Groeneveld PH, van der Werf TS, Gisolf EH, Richter C.
    AIDS Patient Care STDS; 2010 Jun 20; 24(6):361-6. PubMed ID: 20515418
    [Abstract] [Full Text] [Related]

  • 20. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K, Wallace RJ, Bellman PC, Norris D, Fisher RL, Ross LL, Liao Q, Shaefer MS, TARGET Study Team.
    J Infect Dis; 2001 Feb 15; 183(4):571-8. PubMed ID: 11170982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.